The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

List of drugs account for $41 billion in annual Medicare spending, the Biden administration said.